CFTR and cystic fibrosis: 2014). The detection rate of these panels varies depending on the mutations included and the molecular heterogeneity of each population. For many patients with common CFTR mutations that are present in these commercial panels, there is no need for additional studies. However, the high heterogeneity of CFTR mutations in some CF populations and in CFTR-RD often requires the complete molecular screening of the 27 exons and the regulatory regions of CFTR, a putative costly and labor-intensive task.